Physician profile
Gorby Leon
NPI 1679911762
$924.84
in general payments reported to CMS, 2019-2025
15 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.19 · 2021: $72.20 · 2022: $67.08 · 2023: $238 · 2024: $287 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $238.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $124.37 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $100.21 | 2022-2025 | |
| Pfizer INC. | $96.93 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $74.07 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals Lp | $60.45 | 2019-2024 | Airsupra, Farxiga |
| Amgen INC. | $52.77 | 2019-2025 | Otezla, Repatha |
| Dexcom, INC. | $40.43 | 2023-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $34.28 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $20.94 | 2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $20.78 | 2025 | Trelegy Ellipta |
| Ascensia Diabetes Care US INC. | $18.10 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.29 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $14.52 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gorby Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.